Effectiveness and Safety of Intralesional Dutasteride in Patients With Androgenic Alopecia: A Systematic Review and Meta‐Analysis
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70560 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Abdullah Almeziny und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Dutasteride, Alopecia, 5-alpha Reductase Inhibitors. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Androgenic alopecia (AGA) is a common condition characterized by progressive hair loss influenced by dihydrotestosterone (DHT). While oral dutasteride has shown efficacy in treating AGA, concerns about systemic side effects have prompted interest in localized treatments such as intralesional administration.
Aims
This systematic review evaluates the effectiveness and safety of intralesional dutasteride for treating AGA in adults.
Methods
Following PRISMA guidelines, we conducted a comprehensive search of multiple databases for studies involving adults (≥ 18 years) with AGA treated with intralesional dutasteride. Eligible studies included randomized controlled trials, non‐randomized studies, cohort studies, and observational studies. Exclusion criteria were animal studies, duplicate publications, and studies lacking relevant outcome data. The primary outcomes were improvements in hair density, hair thickness, and photographic evidence of hair growth. Secondary outcomes assessed safety, including local and systemic adverse events. Data extraction and quality assessment were independently performed by two reviewers.
Results
Included studies consistently reported improvements in hair density and thickness following intralesional dutasteride treatment, with photographic evidence supporting visual improvement. Treatment was generally well tolerated, with minimal adverse events such as mild scalp irritation and no significant systemic effects reported. However, the studies varied in methodology, sample size, and follow‐up duration.
Conclusions
Intralesional dutasteride appears to be a promising treatment option for AGA, offering localized efficacy with a favorable safety profile. Nonetheless, the current evidence is limited by heterogeneity and a lack of large‐scale, high‐quality trials. Further standardized research is needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia.
- Dermatology Department, King Fahad Hospital, Albaha, Saudi Arabia.
- College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- College of Medicine, Umm Al-Qura University, Al-Qunfudhah, Saudi Arabia.
- Qassim University, Buraydah, Saudi Arabia.
- King Salman Medical City, Medinah, Saudi Arabia.
ORCID-Profile: Abdullah Almeziny, Asail Alghamdi
Zitieren
APA
Almeziny, A., Alghamdi, A., Alajlan, A., Almarhab, N. A., Almatham, A. E., Shaheen, E. A., Altalhab, S., & Alkhalifah, A. I. (2025). Effectiveness and Safety of Intralesional Dutasteride in Patients With Androgenic Alopecia: A Systematic Review and Meta‐Analysis. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70560
Vancouver
Almeziny A, Alghamdi A, Alajlan A, Almarhab NA, Almatham AE, Shaheen EA, et al. Effectiveness and Safety of Intralesional Dutasteride in Patients With Androgenic Alopecia: A Systematic Review and Meta‐Analysis. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70560
BibTeX
@article{Almeziny2025,
author = {Almeziny, Abdullah and Alghamdi, Asail and Alajlan, Alhanoof and Almarhab, Norah A and Almatham, Areen E and Shaheen, Esraa A and Altalhab, Saad and Alkhalifah, Abdullah Ibrahim},
title = {Effectiveness and Safety of Intralesional Dutasteride in Patients With Androgenic Alopecia: A Systematic Review and Meta‐Analysis},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70560}
}
EUVIMED